DaVita Inc. (DVA) Earnings Call Transcript & Summary
May 2, 2024
Earnings Call Speaker Segments
Nic Eliason
executiveThanks for joining us for this call covering our first quarter, and we're glad you remain interested in what our company is doing. I serve as Group Vice President of Investor Relations, and my name is Nic Eliason. With me on the line are Javier Rodriguez, who is our CEO, and our CFO, Joel Ackerman. Before we go further, be aware that statements we might make today could look ahead, falling within the meaning of the federal securities laws. Known and unknown risks and uncertainties apply to each of those statements, and those risks and uncertainties might cause results in reality to differ materially from what such forward-looking statements describe. If you want more information about those risks and uncertainties, turn to the earnings press release for our first quarter along with our SEC filings, which take in our latest annual report on Form 10-K, every quarterly report on Form 10-Q that followed, and any other filings we later submit to the SEC. What we say about the future rests on information available to us right now, and we have no intention of updating such statements, nor do we take on any duty to do so, unless the law demands it. One more thing: some non-GAAP financial measures will come up during this call. You can find a reconciliation between those non-GAAP measures and the closest comparable GAAP financial measures in our earnings press release, which was furnished to the SEC and can be accessed on our website. At this point I'll hand things over to Javier Rodriguez.
Javier Rodriguez
executiveThank you, Nic, and I appreciate everyone taking the time to be with us on this call. Throughout Q1, we kept building on the momentum we generated during 2023, showing operational discipline while still seeking out chances to invest, innovate and, above all, deliver clinical excellence. On today's call, I'll go over our results for the first quarter, offer some detail on our growing international business and finish with an update regarding the Change Healthcare claim disruption. Before diving into how we performed in Q1, I'll begin, as we always do, with a clinical highlight. A key strategic goal of ours is delivering solutions to patients at each stage of the kidney care journey, which includes helping support transplantation. We aspire to make it possible for the greatest number of patients to receive this life-changing gift. Let me call out 3 ways DaVita is working to tackle the systemic obstacles surrounding kidney transplant. The first involves referrals of patients to transplant centers. We just hit our highest monthly rate, with over 2/3 of DaVita patients younger than 75 years old receiving a referral for transplant. The second involves living donation. Living donor counts in the United States have been basically flat across the last 2 decades. To spur more living donors, we teamed up with the National Kidney Foundation on its Big Ask, Big Give campaign, which educates the community about living donation. We additionally gave patients a variety of resources to help them through conversations regarding living donation. And last, since a gap exists in transplant rates across race and ethnicity, we established a new Health Equity Learning Lab. Through the use of transplant navigators, we are testing novel approaches aimed at driving a fairer distribution of patients who succeed in their pursuit of a transplant. Thanks to these efforts and others, over 8,000 DaVita patients obtained a kidney transplant during 2023, which is the largest annual transplant count in our history. Sadly, the biggest obstacle remains a limited supply of organs. You might have come across recent stories concerning compassionate care cases that involve genetically engineered-pig kidneys. This marks an exciting first step as society looks toward a future in which organ availability stops being a constraint for patients who live with kidney disease. This technology is still in its early days, since human trials will require some time; in the interim, we'll keep investing in transplant and take part in innovations that improve access to this life-changing outcome. Moving to how we performed in Q1. Adjusted operating income came in at $463 million, while adjusted earnings per share from continuing operations was $2.38; we enjoyed a strong quarter across our core financial trilogy, with treatment volume and patient care costs landing in line with what we expected and incremental upside coming from revenue per treatment. Our Q1 performance gave us greater confidence in our full year expectations, so we're lifting the bottom end of our adjusted operating income guidance, which puts our updated range at $1.875 billion to $1.975 billion. Looking at these consolidated numbers, our operations outside the U.S. represent an expanding portion of DaVita's overall portfolio. Let me remind everyone that our approach internationally rests on 3 main tenets. First, we seek out markets that let us put money into clinical differentiation and deliver great standards of care for our patients. Second, we choose countries where a route exists to reach meaningful scale, guided by capable local leadership teams. And last, we maintain the same commitment to capital-efficient expansion and appealing risk-adjusted returns that governs every one of our business segments. Acting on those tenets, during March we reached an agreement to put $300 million toward growing what we do in Brazil and Colombia while entering Chile and Ecuador, doing so via purchases of top-quality centers across those 4 markets. The Chilean deal has been completed, while the Ecuador, Colombia and Brazil transaction still needs approval from antitrust and regulatory authorities in each respective country, something we anticipate wrapping up at differing points across 2024. Deals taken opportunistically, like this one, fit with how we allocate capital across the whole enterprise. Looking ahead, we'll keep watching the market for acquisition targets matching our investment criteria, and apart from that we anticipate international investment staying roughly in line with what we've historically spent. If these transactions are completed and added to what we already run, we'd become Latin America's biggest dialysis provider. After these purchases finalize, we'll deliver care across 13 nations beyond the United States, with over 500 centers serving roughly 80,000 patients and staffed by close to 20,000 health care professionals. For 2024, we anticipate international growth adding around $20 million, or roughly 1 percentage point, to DaVita's total enterprise growth in adjusted operating income. Above all, our clinical results abroad keep standing out. We beat the clinical benchmarks in every international market where we do business, and since 2021 we've cut hospitalizations throughout all countries by 11%, which has lowered needless health care spending and amounts to a significant gain for our patients' lives. And last, allow me to address our experience with the Change Healthcare outage and our current position. In the past, the overwhelming majority of our U.S. dialysis claims moved through the Change platform. Like numerous providers, this created a difficult circumstance during the back half of Q1, since we couldn't submit claims via that channel. As our first quarter balance sheet shows, the rise in days sales outstanding and in borrowing under our revolving credit facility stemmed entirely from the Change outage. Joel will go into further detail, but in short, billing activity has restarted, and we're bringing in cash far above normal amounts as we work through the claims backlog. As things stand now, we consider the operational effects of the Change Healthcare disruptions to be mostly behind us. I'll hand things over to Joel now so he can walk through our financial performance and outlook more thoroughly.
Joel Ackerman
executiveThanks, Javier. For the first quarter, adjusted operating income came in at $463 million. Adjusted earnings per share stood at $2.38, while free cash flow was negative $327 million. Our Q1 performance shows solid core operations, along with effects from claims submission and payment delays tied to the Change Healthcare outage, which I'll get into in a moment; so let me walk through the quarter's details. Compared with Q4, U.S. dialysis treatments per day were a bit lower in Q1, which matches what we expected for the quarter. Q1 marked our fifth straight quarter of growth in year-over-year new-to-dialysis admissions, even though mortality is still elevated compared with pre-COVID levels. For the full year, we're keeping our expectation of 1% to 2% treatment volume growth. Revenue per treatment fell by roughly $2 from one quarter to the next; that's mainly because of usual seasonality tied to patient coinsurance and deductibles, partly offset by standard rate increases, contracted escalators, and mix improvements. RPT continues to show strength thanks to revenue cycle improvements, and we're moving toward the upper end of our initial RPT range of 2.5% to 3% growth year-over-year. Non-GAAP patient care cost per treatment dropped $8 on a sequential basis, coming down from a seasonally elevated fourth quarter. Keep in mind that Q4 seasonality ran higher than usual, and that's reflected in the sequential quarterly change. International adjusted operating income rose $15 million sequentially, returning to normal after a Q4 low tied to higher bad debt reserves. On top of that, Q1 got a boost from foreign exchange tailwinds. As Javier said, during this quarter we announced acquisitions across 4 Latin American countries, including our entry into Chile and our planned entries into Ecuador. Those acquisitions should close at different points in 2024, and we expect their partial year operating income in 2024 to be largely offset by acquisition-related expenses. Moving to cash flow and capital allocations. In our quarter-end numbers, you'll notice U.S. dialysis days sales outstanding rose by 19 days. At quarter's end, we had drawn $765 million on our revolver, which pushed our leverage ratio up to 3.3x at the close of Q1. As Javier pointed out, these increases stem directly from the Change Healthcare outage. Since the Change platform came back online, these metrics have improved significantly. We've caught up and are now current on primary claims submission. Cash receipts are still catching up, and we've completely paid down the $765 million revolver draw using a mix of strong April cash flow and interest-free funding from UnitedHealth Group, Change's parent company. By the close of Q2, we expect most of the DSO increase to have reversed. During Q1, we repurchased 2.1 million shares, but as a precaution, we paused our share repurchases in March because of the Change disruption. Given where things stand today, we expect to restart share repurchases, subject to our usual capital allocation considerations. Turning now to the full year 2024, we're revising our guidance for adjusted operating income to a range of $1.875 billion to $1.975 billion, which represents a $25 million lift at the midpoint compared with what we previously provided; in addition, we're revising our EPS guidance to a range of $9 to $9.80; that brings my prepared remarks for today to a close. Operator, please open the call for Q&A.
Andrew Mok
analystRegarding treatments each day — I'd like to build on what was just said. My sense is that it matches what you anticipated. They declined from one quarter to the next, while the normalized increase rose 40 basis points compared with a year earlier. So, first, I'm trying to figure out whether anything affected the quarter, be it weather or other seasonal factors. And second, how much confidence do you have in reaching 1% to 2% treatment growth for the full year? What kind of visibility exists around that? And what will propel it going forward?
Joel Ackerman
executiveYes. Thank you, Andrew. The major factor separating the year-over-year figure for treatments each day from the NAG figure, or the treatment figure, is really day mix. Q1 in '24 contained one additional Tuesday, and New Year's Day fell on a Monday, which means roughly half the volume shifts over to Sunday. Together, those 2 factors can produce a volume swing exceeding 0.5 point. So in my mind, Q1 year-over-year represents a positive figure of 40 or 50 bps of growth versus a year ago, yet as you pointed out, that sits under the 1% to 2% range. When I consider how to connect the 1% to 2% range with the Q1 figure, I'd highlight 2 items. The first concerns clinic closures. How clinic closures were timed during the back half of 2023, along with the pattern we anticipate for '24, creates a volume drag early in '24, though considerably less across the following 3 quarters. That's one. The second is that seasonality is significant, affecting both new-to-dialysis admits and mortality, and it can shift from one month to the next. Simply examining the pattern from '23 against our expectations for '24, we remain confident about 1% to 2% growth, though we believe it will arrive somewhat later in the year than we had expected. So I'd stress once more, Q1 matched our expectations, with the overall pattern of strong new-to-dialysis admits offset by ongoing mortality challenges. Nothing there has shifted, and we remain confident about 1% to 2% for the year.
Andrew Mok
analystUnderstood. Then regarding what you mentioned about mortality, I believe you noted it stays higher than it was before COVID. Are there any patterns in how it has moved, whether comparing one year to the next or one quarter to the next, after COVID?
Joel Ackerman
executiveSince hitting its highest point, it has by and large dropped considerably. It shifts around quarter by quarter, and honestly, pinpointing exactly where Q1 ended up is still somewhat premature. Mortality isn't something we learn about, as you're aware, until a couple of months following the period; so we're watching it closely; it's — like I mentioned, it's fallen a great deal, yet it's still above normal.
Andrew Mok
analystUnderstood. All right, then perhaps one additional item regarding expenses tied to patient care. The cost for each treatment declined by another 1% compared with the same period a year earlier, and I believe 3% on a sequential basis. Is there anything specific worth highlighting that contributed to these robust figures?
Joel Ackerman
executiveYeah. On a sequential basis, a great deal of it relates to the elevated seasonality observed during Q4, which we had flagged. Compared with the prior year, wage-related pressure persists, as we have mentioned, and it is being counterbalanced relative to Q1 of '23 through reduced contract costs along with a gain in productivity during the quarter.
Pito Chickering
analystRevenue for each treatment was quite impressive this quarter. Did HIX sign-ups drive that, or were there some one-off items involved? Normally, as copays and deductibles get used up, it rises about $4 to $5 from one period to the next. Should we think of it that way — is that the correct approach for the remaining months of the year?
Joel Ackerman
executiveYes. That seems accurate to me. The typical Q1 pattern of roughly $5 per treatment showed up in this quarter. So in Q2 and beyond, we would anticipate that RPT would reflect that increase. Regarding anything out of the ordinary this quarter, there is nothing I would point to. The Q1 figure, in my view, is a fairly clean one to use as a basis for projecting the remainder of the year.
Pito Chickering
analystAll right. So that's kind of running ahead of what you've projected, correct? Like, if we go back to roughly the revenue per treatment figures you're steering toward, you're essentially pointing to nearly mid-single digits. I mean, a bit — beyond the sort of 3% band, and that's already happening and keeps going, right?
Joel Ackerman
executiveWe're basically at the upper end of that band, close to 3%. If you look at the guidance as a $25 million increase at the midpoint, and you chalk that up to RPT, which I'd say is a reasonable way to view it, that would land you at about 3% year-over-year.
Pito Chickering
analystSure, that makes sense. Since adjusted operating income came in $39 million above expectations and you raised guidance by $25 million, did the Street build its Q1 operating income model incorrectly? Once again, it seems the upper bound of your range wasn't increased. I'm simply asking whether that's a detail you might be missing. Also, is there any obstacle to taking Q1 OI and multiplying by something like 23% to get to about $2 billion? If the trends continue as they have, wouldn't that be the right way to think about the eventual outcome should Q1 trends hold?
Joel Ackerman
executiveYes. Okay, so seasonality — in my view, there are definite patterns to it, even if they move around from one year to the next. Probably the most obvious piece of that seasonality is the RPT pickup we get coming out of Q1. Beyond that, wage pressure usually builds as the year goes on, and the same is true for other components of RPT, though wage pressure generally runs higher. Then Q4 expenses frequently climb because of year-end and other items. So, just like we saw in '23, Q4 has brought some genuinely negative seasonality for us. All of that relates to U.S. dialysis. IKC is harder to predict; our performance is usually stronger in the latter part of the year. However, as you're aware, that pattern can shift annually, so taking Q1 and multiplying by four isn't the ideal approach to arrive at the figure. Actually, if you took our OI and annualized it, the result would land slightly under our range. Therefore, you need to make an adjustment for the RPT. You also have to factor in the seasonal softness in Q4, and then you'd arrive at a number within our range.
Pito Chickering
analystAll right, excellent. Then here's a brief question about figures. Could you put a figure on how many individuals started dialysis treatment during this quarter compared with the same period a year ago?
Joel Ackerman
executiveI can't give you a specific figure. Usually that figure rises roughly in line with volume growth — roughly matching the volume growth figures we've seen historically — and my sense is that this quarter falls right within that same pattern.
Kevin Fischbeck
analystOkay, so regarding the RPT, it sort of looks as though you're lifting the outlook because of how well that did this quarter, instead of assuming that stronger pace will keep up. Is that right? Or do you mean the guidance now presumes that elevated pace carries on for the remaining portion of the year?
Joel Ackerman
executiveWe aren't increasing it on the premise that this outperformance lasts all year; the quarter exceeded what we anticipated, yet I don't believe you'd take that and times it by 4 to arrive at the updated figure.
Kevin Fischbeck
analystSo what explains that? Based on what you're describing, there's something out of the ordinary going on here. So why — going back to what Pito asked earlier, why wouldn't this just be the usual seasonal growth for the sector, and then carry through each quarter?
Joel Ackerman
executivePart of the reason, I believe, is the way we had modeled it across the year, and what actually happened — the pattern that emerged was somewhat different from what we had anticipated.
Kevin Fischbeck
analystAll right. So the figure you had for the close of the year was larger, and based on what you observed in Q1, you're simply reaching it more quickly.
Joel Ackerman
executiveThat's right.
Kevin Fischbeck
analystAll right. Then, I suppose, regarding the IKC segment specifically, clearly, quite a bit of attention is being paid to the trajectory of costs among Medicare Advantage carriers, and they appear wildly inconsistent from one year to the next. What you've gone through will differ somewhat from Medicare Advantage at large, but I'd really like to hear your perspective on how utilization is unfolding across the managed programs you operate?
Javier Rodriguez
executiveSure. I'll take that. What people ask me frequently is this: why do MA companies focused on kidney care report conflicting observations? The truth is that utilization across the wider MA membership carries greater swings. Our members, despite having numerous coexisting illnesses, are easier to forecast, which means we see fewer fluctuations. On top of that, as you're aware, the wider MA space underwent certain coding modifications that never affected our membership. That, once more, eliminates part of the instability they are dealing with. As a result, the patterns we observe are considerably steadier among the people we serve. Is that a satisfactory response to what you asked?
Kevin Fischbeck
analystK (Kevin Fischbeck): Yeah. No, that answers it. I take it you're essentially telling us it's landing right where expected — neither above nor below your forecast thus far in Q1.
Javier Rodriguez
executiveJ (Javier Rodriguez): That's right.
Kevin Fischbeck
analystAll right. Perhaps just one final item, then. Regarding that overseas acquisition, it seems like you folks are genuinely enthusiastic about it; we've often found ourselves curious about how it works when a big player sells off something and then a different big player steps in? How do you approach the question of what your contribution to those assets could be? Or what's your thinking on where the opportunity lay, assuming somebody else with comparable options concluded it was the right moment to leave.
Javier Rodriguez
executiveThat's an excellent question, and we aren't so full of ourselves as to claim we run things better than others. Our view is that economies of scale open up certain efficiencies. We already had a footprint in those nations, plus offices available that we could put to work. So essentially, the business's fixed portion got leveraged more substantially; that, I believe, explains how one party can walk away while another party, as you can observe, finds it a compelling asset. Still, as we mentioned at the outset, we apply our standard criteria around clinical differentiation. Our aim was to grow and assist them in growing, and we believed a solid, appealing return adjusted for risk was within reach.
Dean Rosales
analystThis is Dean Rosales, filling in for Justin. Could you provide any details regarding wage inflation? What figure are you factoring in for the year? Then my second question: is there any news on how mistreatment rates are trending quarter over quarter, and year over year? Are there any patterns?
Joel Ackerman
executiveSure. Regarding wage inflation, we mentioned at the start of the year that we anticipated roughly 5%, and it's been monitoring quite in line with our expectations; so there isn't much to report there. As for the mistreatment rate, it's behaving as we mostly anticipated, meaning it's gradually getting better each year following COVID, nothing major to highlight. The size is fairly minor. We believe we'll return to our historical mistreatment rate across a few years. So for any particular year, it isn't truly a meaningful figure.
Dean Rosales
analystUnderstood. And for the final question, what ought we to anticipate regarding center consolidations for the rest of the year?
Javier Rodriguez
executiveThank you, Dean. My sense is that the figure will land at roughly 30 closures on a net basis — that is the appropriate figure to use for net build and closures.
Gary Taylor
analystTo build on that previous point, is that 30 net across the coming three quarters, or does it apply to the entire year?
Javier Rodriguez
executiveIt applies to the entire year.
Gary Taylor
analystUnderstood. So, the first thing I'd like to say is that I have to give you credit for delivering margin expansion that goes far beyond anything the Street can put into a model. This makes, I believe, the third consecutive quarter in which you've delivered OI growth of 30% to 50% on revenue growth of 6% to 8%. That is truly remarkable cost management, productivity, everything you folks are doing. Once we lap that, so perhaps there's one more quarter in it, but as we move into the back half of '24, are there still solid grounds to think that this operating leverage can be maintained at a level above your long-term OI guidance of 3% to 7%, like what would be a few key swing factors that would make one optimistic that some degree of operating margin leverage will persist?
Joel Ackerman
executiveYes; so to begin, Gary, I appreciate those kind remarks. Looking ahead, I don't believe we are altering our long-term OI growth figure of 3% to 7%. So that's where I'd begin; having said that, I also don't believe we are exhausting the opportunities to keep running the business effectively and provide high-quality clinical care to our patients and keep enhancing our bottom line and possibly our margins. I would stress that we've accomplished this not solely through cost reduction, correct? A great deal has been done on the revenue side that has come through nicely; but I think additional opportunities exist too. Further advancement on IKC would be among them. I think improvements in capacity utilization would be another significant one I'd mention. I think there are other pieces of our cost structure, which might be productivity, might be other nonlabor-related items that we can keep managing; so I don't sense that we are running out of ideas. Having said that, we are also not prepared to lift our long-term OI guidance beyond 3% to 7%.
Gary Taylor
analystThis might be my final question. I'd like to get a better handle on tender consolidations, if possible. Looking at average patients per center, that's definitely been high across multiple years. And within just the past 2 years, I believe patients per center has climbed 9% over a couple of years, and your margins got better by nearly 300 basis points while that was occurring. A portion of that comes from consolidation. Another portion comes from growth in your home programs fueling it. Going forward, does this remain an important lever, or does it extend past the 30 centers Javier mentioned?
Javier Rodriguez
executiveWell, I believe the — allow me to clarify, since a few of those figures didn't quite land with me, though perhaps we can sort them out right here. A better framework, I think, is to consider our performance on center utilization, and before the excess mortality, when we were preclosing these centers, utilization sat in the mid-60s. At present, utilization stands at 58-ish percent; as a result, we have additional capacity on hand, which means we're less inclined to need to put capital toward constructing centers. And although our home has gotten better, the improvement hasn't been all that large. Patients at home remain roughly 15% of our mix. So with luck, that clears up a few of those points.
Joel Ackerman
executiveAbsolutely. Gary, building on Javier's point, there's one more thing worth mentioning: we have room to boost capacity utilization without shutting down additional centers. What we're doing is simply taking in the growth in treatment volume within the footprints we already have.
Gary Taylor
analystAdding shifts, adding machines.
Joel Ackerman
executiveRight.
Albert Rice
analystThank you, everyone. To start, I'd like to ask about how IKC is trending. I understand your projection for '24 was a loss of roughly $50 million. And in Q1, as I recall, you're sitting at $26 million. I realize seasonality plays a role, and there are all sorts of other dynamics at work. Still, I'm curious whether you'd characterize things as on track. Are you performing somewhat ahead? Or what's the right frame for that?
Joel Ackerman
executiveYes. I'd describe us as mostly on track. This business has quite a bit of seasonality. And clearly, you pick up more information as the year goes on, but Q1's results contained no surprises for us.
Albert Rice
analystAll right. Then, moving on from the fourth quarter, I believe we had estimated — not from your formal guidance, I realize, but our own estimate — that you expect buybacks somewhere between $1 billion and $1.5 billion for '24. Given what you've said about how the first quarter unfolded, do you still think you'll land near that figure? Or should we simply take it that the buyback activity from the first quarter is behind us, and that across the last 3 you'll keep going at the earlier pace?
Javier Rodriguez
executiveWe do still aim for that target, I'd say. Timing clearly plays a part, and we'll keep an eye on it, but getting the whole thing finished remains our ambition.
Albert Rice
analystAll right, and as a final point, a follow-up inquiry plus some remarks regarding that overseas purchase. My impression is that, from your perspective, this was more of a chance opportunity that presented itself and lets you, as you put it, gain traction in particular markets while breaking into some additional ones. Does anything on the global side suggest to you that the level of dealmaking there might accelerate?
Javier Rodriguez
executiveNo. I believe you're viewing it correctly — we behave opportunistically, and we continually seek out a transaction satisfying the standards we've set forth. Should we fail to locate one, we won't proceed; should we locate one, we will. Consequently, there's no pressure or haste, just conducting business with discipline and in line with our plan.
Lisa Clive
analystI have a few things I'd like to ask. Regarding those utilization numbers you gave, that only reflects your in-center patient group, correct? I'm trying to figure out how to factor in total patients on top of that, assuming that group keeps expanding at a quicker pace than your in-center patients, and whether that basically raises the patient count per clinic, but as far as utilization goes, you're only considering the in-center side. Then my second thing: can you share the share of your patients currently receiving MIRCERA? I just want to get a sense of how much additional expense reduction you might still achieve from that switch. And finally, any initial views or remarks regarding online hemodiafiltration? I'd guess that in your European facilities, you rely on that technology. Clearly it's still uncertain how soon FMC can get those machines out and build up capacity to market them in the U.S., but I'd really like to hear what you think.
Javier Rodriguez
executiveSure. I'll address them one by one. Should I overlook something, kindly prompt me; regarding utilization, that figure represents chronic center utilization, and the way a home should be viewed is that it can obviously accommodate patients far more easily and with significantly less capital outlay. So you're correct that the utilization figure we provided is in-center. When it comes to MIRCERA, essentially the overwhelming majority, arguably all, have now moved to MIRCERA; so that has fully unfolded. Then regarding hemodiafiltration, I believe it will be intriguing to watch how that unfolds across the United States since it's — as you're aware, it's permitted in numerous countries. And the data we possess are truly inconsistent, meaning that in certain nations, the overwhelming majority of patients receive it. Whereas in other nations, only a minuscule share of patients receive it. So although there are 1 or 2 studies suggesting it might be superior since it clears the mid molecules, there are plenty of flaws you can find in those studies, so we'll need to observe how that unfolds. And then, naturally, the FDA cleared the machine, yet we lack any reimbursement direction. So ultimately, you'll need to factor in, first, what the physician prefers, what the patient prefers, since that treatment might require additional time, and then layer the economic model on top of that; so there are an excessive number of variables still awaiting definition for us to gauge it in any useful manner.
Javier Rodriguez
executiveAll right. So, Michelle, I appreciate that, and thanks to everyone for your questions and your interest in DaVita. Like we talked about during the call, the year has begun well for us. And naturally, we'll keep putting in the effort to maintain that course. Above all else, we stay focused on delivering excellent clinical care to the people we treat. Thanks to each of you for being on the call, and take care.
Operator
operatorThanks, and that wraps up the conference call for today. At this point, you’re welcome to go ahead and disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.